Alkermes reported robust third-quarter results, driven by strong product performance and strategic advancements, prompting an increase in 2025 financial guidance.
- Total revenues reached $394.2 million, with proprietary product sales increasing 16% year-over-year to $317.4 million.
- The proposed acquisition of Avadel Pharmaceuticals is expected to enhance Alkermes' position in the sleep medicine market and diversify its product portfolio.
- GAAP net income for the quarter was $82.8 million, demonstrating strong profitability alongside a significant gross-to-net benefit from Medicaid utilization.
- Research and development expenses rose to $81.7 million, reflecting investment in ongoing and upcoming clinical studies for orexin receptor agonists.
- Full-year 2025 guidance increased, underlining confidence in sustained commercial traction and operational execution.
Community Discussion